The Octapharma Co-Pay Assistance Program
Savings & Support Made Simple
The Octapharma Co-Pay Assistance Program can provide you with significant savings on some of the costs associated with your factor products. If you're currently using a factor product from Octapharma, or if you're about to begin therapy, our Co-Pay Program can offer savings up to $6,000 per year on the out-of-pocket costs associated with your therapy.
To be eligible...
For more information or to enroll, contact the Octapharma Support Center at: 1-800-554-4440
Octapharma reserves the right to amend this offer without notice.
Indications and Usage
wilate® is a von Willebrand Factor/Coagulation Factor VIII Complex (Human) indicated in children and adults with von Willebrand disease for on-demand treatment and control of bleeding episodes, and for perioperative management of bleeding. wilate® is not indicated for the treatment of hemophilia A.
Important Safety Information
Hypersensitivity or allergic reactions have been observed upon use of wilate® and may in some cases progress to severe anaphylaxis (including shock) with or without fever.
When using a factor VIII (FVIII)-containing von Willebrand Factor (VWF) product, the treating physician should be aware that continued treatment may cause excessive rise in FVIII activity. Monitor plasma levels of VWF:RCo and FVIII activities in patients receiving wilate® to avoid sustained excessive VWF and FVIII activity levels, which may increase the risk of thrombotic events.
Patients with VWD, especially type 3 patients, may potentially develop neutralizing antibodies (inhibitors) to VWF, manifesting as an inadequate clinical response. Since inhibitor antibodies may occur concomitantly with anaphylactic reactions, patients experiencing an anaphylactic reaction should also be evaluated for the presence of inhibitors.
wilate® is made from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, eg, viruses and, theoretically, the variant Creutzfeldt-Jakob disease (vCJD) agent or other unknown infectious agents, cannot be completely eliminated. Despite measures to reduce this risk, such products may still potentially transmit disease.
The most common adverse reactions to treatment with wilate® in patients with VWD have been urticaria and dizziness. The most serious adverse reactions to treatment with wilate® in patients with VWD have been hypersensitivity reactions.
To report suspected adverse reactions, contact:
Octapharma USA Inc.
FDA at 1-800-FDA-1088 or